Condition: Melanoma · Sponsor: Jun Guo
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
This description comes directly from the study's public registry record.
Jun Guo · 86-10-88121122 · guoj307@126.com
Bin Lian · 86-10-88121122 · lianbin0214@126.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05983237